Malignancies associated with DPP4 inhibitors and GLP1 receptor agonists: Data from a large real-world database.
Malignancies associated with DPP4 inhibitors and GLP1 receptor agonists: Data from a large real-world database.
复制标题
与 DPP4 抑制剂和 GLP1 受体激动剂相关的恶性肿瘤：来自大型现实世界数据库的数据。
DOI：
10.1200/jco.2020.38.15_suppl.1567
复制
发表时间：
2020
影响因子：
45.3
通讯作者：
Chang H. Kim
中科院分区：
文献类型：
--
作者：
Jiasheng Wang;Chang H. Kim
1567背景：DPP 44抑制剂（DPP 4 i）和GLP 1受体激动剂（GLP 1 Ra）通过促进GLP-1通路控制2型糖尿病（T2 DM）;其激活可导致发育异常或肿瘤抑制基础。
1567Background: DPP44 inhibitors (DPP4i) and GLP1 receptor agonists (GLP1Ra) control type 2 diabetes (T2DM) by promoting GLP-1 pathway; its activation can lead to dysplasia or tumor inhibition base...